• U.S. business grew strongly with $A7.0m in monthly sales
• Rest of World had $A3.1m in monthly sales
• Total group revenue, including BARDA, was $A11.0m for the month

PolyNovo Ltd, a medical device company focused on Advanced Wound Care, has reported a record monthly sales of $A10.1m (unaudited) for November 2024. The company's U.S. business grew strongly, with monthly sales of $A7.0m, and YTD November sales of $A33.9m, up 27.3% on the same period last year. The Rest of World market also performed well, with monthly sales of $A3.1m and YTD November sales of $A10.5m, up 24.0% on the same period last year. The company continues to disrupt the market by expanding into soft-tissue reconstruction use cases in the UK and Germany, displacing the current gold standard in oncological excisions and surgical dermatology. Total group revenue for the month, including BARDA, was $A11.0m (unaudited), and YTD November group revenue of $A49.6m is up 25.4% on the same period last year. The company is now supplying 46 countries and is proud of the humanitarian outcomes being delivered in those countries, including where product has been supplied for free.

The company continues to be grateful to its clinicians, partners, and people, who are coming together to ensure that NovoSorb is rapidly embraced as a soft-tissue reconstruction platform of choice across Plastic and Reconstructive surgery. The company's new monolayer product, NovoSorb MTX, is on a steep adoption curve in the U.S.